



Innovative back microsurgery

Press release

VEXIM strengthens his management team with the appointment of Gunther Peeters as VP Sales Europe & Global Marketing, and Remco Maljers as VP Indirect Sales & Business Development

Toulouse, 11 June 2015 - VEXIM (FR0011072602 – ALVXM / Eligible PEA-PME), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces the appointments of Gunther Peeters as VP Sales Europe & Global Marketing and Remco Maljers as VP Indirect Sales & Business Development, both effective in May 2015.

With over 13 years of experience in the Healthcare Industry, Gunther Peeters, 35, started working as a Sales Representative for Sandoz (Novartis Generics) in 2002 moving to a territory manager function until making the transition into Medical devices in 2007, when he started helping Spinal Kinetics with their Artificial Disc Replacement technology enter the OUS markets. He was co-responsible for commercializing their products and building the business in all major markets with great success, all the way up to reaching the critical milestone of 25,000 implants achieved in 6 years of time. Since 2013, Gunther accepted a new challenge when he joined the R&D start-up, Orthobion GmbH, in Germany. Orthobion was a developer of innovative interbody fusion implants, that were treated with a specialized surface and coating procedure. He was responsible for product-development, working closely with key EU surgeons alike, and setting a pathway for the company's first commercial successes in the EMEA region. He graduated an MBA in International Business Management from Vlerick Business School, as well as a Master Management degree from London Business School. Gunther has extensive experience in Business development, Sales, Clinical education, Marketing, as well as Regulatory and Clinical, where he will help provide benefit at Vexim.

Remco Maljers, 43, has 20 years of experience in Sales and Marketing and specialized in the global orthopedics and spinal industry. He started his career in spine at Medtronic Sofamor Danek where he has held several international marketing positions during 3 years (2002-2005). There, he notably launched and introduced the TSRH-3D system on the European market, a thoracolumbar pedicle screw system. From 2005 to 2012, he was responsible for establishing the distribution network in Central and Eastern Europe, Middle East and Africa at Wright Medical. Prior to joining VEXIM, Remco worked as a VP Global Sales at Intrinsic Therapeutics (2012-2015), where he was responsible for building up the distribution network across the Globe. During that time he successfully obtained the reimbursement of the Barricaid Annular Closure Device from the Australian Ministry of Health. Passionate by the industry and with exceptional experience, Remco brings an extensive network of spinal surgeons and healthcare professionals from around the globe. He holds a Bachelor degree in Marketing and Commercial Management and successfully completed executive courses at Harvard Business School and IMD (Institute for Management Development).

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholder, Truffle Capital¹ and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland, the United Kingdom and United States, as well as distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil. Vexim has been listed on NYSE Alternext Paris since May 2012.

For further information, please visit www.vexim.com

SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

Contacts

VEXIM

Vincent Gardès

CEO

investisseur@vexim.com

Tel: +33 5 61 48 48 38

Alize RP

Relations presse

Caroline Carmagnol / Wendy Rigal

vexim@alizerp.com

Tél : 01 44 54 36 66 / 06 64 18 99 59

LifeSci Advisors LLC

Investor Relations

Michael Wood

www.lifesciadvisors.com

+1 646 597 6983



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM



¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.